Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience

The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases. The 3-year PFS was 75.1% for CD20(+)and 70% for CD20(−) (p = 0.36). The 3-year PFS was 84.7% for the rituximab group and 67.8% for...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuelgasim, Khadega A., Shammari, Raed Al, Alshieban, Saeed, Alahmari, Bader, Alzahrani, Mohsen, Alhejazi, Ayman, Alaskar, Ahmed, Damlaj, Moussab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076710/
https://www.ncbi.nlm.nih.gov/pubmed/33936943
http://dx.doi.org/10.1016/j.lrr.2021.100240
Descripción
Sumario:The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases. The 3-year PFS was 75.1% for CD20(+)and 70% for CD20(−) (p = 0.36). The 3-year PFS was 84.7% for the rituximab group and 67.8% for the no rituximab group (p = 0.23). Only constitutional symptoms and positive interim PET/CT were significantly associated with worse outcome, HR 3.2 (1.14–9.01; p = 0.028) and 4.3 (2.27–8.1; p < 0.0001), respectively. Neither CD20 expression nor rituximab use significantly impacted outcome.

Ejemplares similares